Ignite Creation Date:
2024-05-06 @ 2:07 PM
Last Modification Date:
2024-10-26 @ 1:25 PM
Study NCT ID:
NCT04224441
Status:
UNKNOWN
Last Update Posted:
2020-01-13
First Post:
2020-01-07
Brief Title:
Repurposing Chlorpromazine in the Treatment of Glioblastoma
Sponsor:
Marco G Paggi MD PhD
Organization:
Regina Elena Cancer Institute
Study Overview
Official Title:
Repurposing the Antipsychotic Drug Chlorpromazine as a Therapeutic Agent in the Combined Treatment of Newly Diagnosed Glioblastoma Multiforme
Status:
UNKNOWN
Status Verified Date:
2020-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RACTAC
Brief Summary:
This study evaluates the addition of chlorpromazine to the first-line therapeutic protocol ie maximal well-tolerated surgical resection followed by radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide in newly diagnosed glioblastoma multiforme patients carrying a hypo-methylated O6-methylguanine-DNA-methyltransferase MGMT gene
Detailed Description:
Chlorpromazine CPZ Largactil Thorazine is a potent antagonist of the dopamine receptor D2 DRD2 and has been effectively and safely employed for over half a century in the treatment of psychiatric disorders CPZ displays a series of remarkable bio-molecular effects in cancer cells as inhibition of cell growth nuclear aberrations inhibition of the phosphoinositide 3-kinasemammilian target of rapamycin PI3KmTOR axis induction of cytotoxic autophagy inhibition of glutamate and DRD2 receptors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None